
Anixa Biosciences ANIX
€ 2.52
2.11%
Quartalsbericht 2025-Q4
hinzugefügt 09.03.2026
Anixa Biosciences Kurzfristige Verbindlichkeiten 2011-2026 | ANIX
Kurzfristige Verbindlichkeiten Jährlich Anixa Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.97 M | 2.5 M | 2.03 M | 2.04 M | 1.27 M | 1.19 M | 1.48 M | 1.27 M | 889 K | 469 K | 594 K | 1.81 M | 3.21 M | 1.82 M | 2.11 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 3.21 M | 469 K | 1.64 M |
Kurzfristige Verbindlichkeiten anderer Aktien in der Diagnostik & Forschung
| Name | Kurzfristige Verbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Akumin
AKU
|
169 M | - | -17.87 % | $ 25.9 M | ||
|
Aspira Women's Health
AWH
|
5.78 M | - | -6.19 % | $ 10.5 M | ||
|
Bioventus
BVS
|
160 M | $ 8.92 | 0.56 % | $ 594 M | ||
|
Castle Biosciences
CSTL
|
49.4 M | $ 26.01 | 0.68 % | $ 722 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
13.8 M | - | - | $ 562 M | ||
|
DexCom
DXCM
|
2.14 B | $ 68.2 | 2.8 % | $ 26.6 B | ||
|
Charles River Laboratories International
CRL
|
1.12 B | $ 154.35 | 1.57 % | $ 7.65 B | ||
|
CareDx, Inc
CDNA
|
89.8 M | $ 17.52 | 1.18 % | $ 934 M | ||
|
Guardant Health
GH
|
303 M | $ 87.53 | 0.4 % | $ 11 B | ||
|
Accelerate Diagnostics
AXDX
|
66.6 M | - | -61.36 % | $ 2.46 M | ||
|
Exact Sciences Corporation
EXAS
|
641 M | $ 103.87 | 0.01 % | $ 19.6 B | ||
|
Global Cord Blood Corporation
CO
|
647 M | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
54.2 M | - | 1.08 % | $ 308 M | ||
|
Fulgent Genetics
FLGT
|
72.9 M | $ 15.53 | 3.88 % | $ 470 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
1.27 B | - | - | $ 10.7 B | ||
|
Biodesix
BDSX
|
14.3 M | $ 17.01 | -1.62 % | $ 2.21 B | ||
|
ICON Public Limited Company
ICLR
|
2.8 B | $ 99.43 | 1.86 % | $ 8.2 B | ||
|
IQVIA Holdings
IQV
|
8.34 B | $ 168.32 | 2.14 % | $ 28.9 B | ||
|
Danaher Corporation
DHR
|
6.81 B | $ 194.97 | 1.87 % | $ 139 B | ||
|
Biocept
BIOC
|
5.51 M | - | -13.05 % | $ 7.29 M | ||
|
Heska Corporation
HSKA
|
39.6 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
8.27 M | - | -20.0 % | $ 1.06 M | ||
|
Illumina
ILMN
|
1.55 B | $ 121.42 | 1.79 % | $ 19.3 B | ||
|
Quest Diagnostics Incorporated
DGX
|
2.28 B | $ 199.2 | 0.13 % | $ 22.1 B | ||
|
QIAGEN N.V.
QGEN
|
544 M | - | - | $ 10.6 B | ||
|
Agilent Technologies
A
|
1.71 B | $ 113.43 | 1.43 % | $ 34.5 B | ||
|
BioNano Genomics
BNGO
|
37.3 M | $ 1.12 | 0.66 % | $ 1.42 M | ||
|
DarioHealth Corp.
DRIO
|
12.5 M | $ 9.28 | 10.24 % | $ 263 M | ||
|
NeoGenomics
NEO
|
88.3 M | $ 8.36 | 1.46 % | $ 1.07 B | ||
|
Neogen Corporation
NEOG
|
174 M | $ 9.24 | 1.43 % | $ 2 B | ||
|
Lantheus Holdings
LNTH
|
333 M | $ 78.46 | -0.05 % | $ 5.3 B | ||
|
Chembio Diagnostics
CEMI
|
39.3 M | - | 0.22 % | $ 16.8 M | ||
|
Pacific Biosciences of California
PACB
|
72.8 M | $ 1.41 | 3.31 % | $ 423 M | ||
|
Check-Cap Ltd.
CHEK
|
1.81 M | - | - | $ 9.42 M | ||
|
Co-Diagnostics
CODX
|
5.75 M | $ 4.4 | 101.83 % | $ 129 M | ||
|
Medpace Holdings
MEDP
|
1.34 B | $ 452.71 | -0.21 % | $ 13.1 B | ||
|
Motus GI Holdings
MOTS
|
3.27 M | - | -34.28 % | $ 263 K | ||
|
Mettler-Toledo International
MTD
|
1.2 B | $ 1 215.3 | 1.35 % | $ 25 B | ||
|
Celcuity
CELC
|
31.7 M | $ 114.14 | -0.66 % | $ 4.5 B | ||
|
DermTech
DMTK
|
13.4 M | - | -11.32 % | $ 2.94 M | ||
|
National Research Corporation
NRC
|
36.6 M | $ 17.95 | 3.16 % | $ 402 M | ||
|
Invitae Corporation
NVTA
|
108 M | - | - | $ 21.2 M | ||
|
Enzo Biochem
ENZ
|
24.8 M | - | -8.98 % | $ 14.8 K | ||
|
Natera
NTRA
|
310 M | $ 199.43 | 0.89 % | $ 19.6 B | ||
|
OPKO Health
OPK
|
193 M | $ 1.2 | 0.42 % | $ 833 M |